Effect of pyridostigmine in stroke-related dysphagia

Investigating the effect of Pyridostigmine to improving dysphagia in stroke patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230520058232N1

Enrollment

Registered

2023-06-26

Start date

2023-07-23

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke related dysphagia. Dysphagia following cerebral infarction

Interventions

Intervention 1: Intervention group: receiving pyridostigmine 120 mg every 12 hours for three weeks. Intervention 2: Control group: receiving placebo every 12 hours for three weeks.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Confirming the diagnosis of stroke disease based on imaging and laboratory results GCS level of consciousness greater than 12 Age above 18 years old

Exclusion criteria

Exclusion criteria: Age less than 18 years hemorrhagic stroke head and/or neck trauma

Design outcomes

Primary

Measure	Time frame
Severity of patients' dysphagia based on the score of Swallowing Disturbance Questionnaire (SDQ). Timepoint: Measuring the score of the questionnaire in patients at the beginning of the study and after the start of treatment until 14 days after the end of treatment. Method of measurement: Swallowing Disturbance Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzaneh Karimian

Sanandaj University of Medical Sciences

fkarimian1363@gmail.com+98 87 1613 1311

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026